Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
Olivieri
N F
NF
Division of Hematology-Oncology, Hospital for Sick Children, Toronto, Canada.
Koren
G
G
St Louis
P
P
Freedman
M H
MH
McClelland
R A
RA
Templeton
D M
DM
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D015913:Chelation Therapy / Q000379:methods*; D002648:Child; D000077543:Deferiprone; D003676:Deferoxamine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D007501:Iron / Q000652:urine; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D010865:Pilot Projects; D011728:Pyridones / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013789:Thalassemia / Q000628:therapy* / Q000652:urine; D065227:Transfusion Reaction
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine